Log in | Register

FTC

FTC Approves Final Settlement with CVS Caremark

May 15 | News

Following a public comment period, the FTC has accepted as final an order with CVS Caremark settling charges that it misrepresented the prices of certain Medicare Part D prescription drugs, including drugs used to treat breast cancer symptoms and epilepsy, at CVS and Walgreens pharmacies.

FTC Chairman Releases 2012 Annual Highlights

Mar 30 | News

Federal Trade Commission Chairman Jon Leibowitz released the agency’s 2012 Annual Highlights today at the spring meeting of the American Bar Association’s Section of Antitrust Law in Washington, DC, recognizing the agency’s continued efforts to protect consumers and promote competition.

FTC Testifies on Proposed Antitrust Exemption for Community Pharmacies

Mar 29 | News

The Federal Trade Commission testified today before Congress about proposed legislation that would exempt independent pharmacies from the antitrust laws, saying that such an exemption is likely to reduce competition and innovation, and ultimately increase prices for health care consumers...

Omnicare Abandons Plan to Buy Rival Pharmacy in Light of FTC Lawsuit; FTC Votes to Dismiss its Complaint Seeking to Block the Transaction

Feb 23 | News

The Federal Trade Commission has dismissed the complaint it issued in January seeking to block Omnicare, Inc.'s hostile acquisition of rival long-term care pharmacy provider PharMerica Corporation, in light of Omnicare's recent decision to abandon the proposed transaction.

CVS Caremark Corporation Settles FTC Deceptive Pricing Charges

Jan 12 | News

Many Seniors and Disabled Consumers Hit With Higher Prices for Prescription Drugs

FTC Protects Consumers by Requiring Valeant to Sell Three Prescription Drugs as Condition to Acquire Rival Dermatology Businesses from Sanofi and Johnson and Johnson

Dec 12 2011 | News

Protecting competition in the market for three topical dermatology drugs, the Federal Trade Commission has approved orders requiring Valeant Pharmaceuticals International, Inc. to divest three drugs used to treat different skin ailments, as conditions of acquiring Ortho Dermatologics,...

FTC Testifies Before House Judiciary Subcommittee on Agency's Work to Promote Competition and Benefit Consumers

Dec 7 2011 | News

In testimony today before a U.S. House of Representatives Judiciary Subcommittee, the Federal Trade Commission detailed its work to promote competition and benefit consumers, including preventing anticompetitive mergers, restricting "pay-for-delay" pharmaceutical agreements that increase...

Statement of FTC Chairman Jon Leibowitz at his Reappointment Hearing before the Senate Commerce Committee

Nov 15 2011 | News

Federal Trade Commission Chairman Jon Leibowitz delivered the following statement at a hearing today before the Senate Committee on Commerce, Science and Transportation to consider his nomination for a second term on the Commission

FTC Requires Parent of Market Research Firm IMS Health to Sell Two Product Lines Before Acquiring Rival SDI Health

Oct 28 2011 | News

SDI's Audit Businesses Must Be Sold to Settle FTC Charges

FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs

Oct 27 2011 | News

FTC Chairman Asks Congressional Supercommittee to Reduce the Deficit and Lower Nation's Health Care Costs by Restricting Pay-for-Delay Deals

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Lung Cancer Drug Treats Rare Lymphoma Tumors

Lung Cancer Drug Treats Rare Lymphoma Tumors

May 17 | Video

A new study found Xalkori effective in treating anaplastic lymphoma among children, an encouraging development for gene-targeted therapy.

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter